May 2025
Dr Lizzy Smyth introduces our Update from ASCO 2025 and shares which of her fellow experts will be joining us to provide their views on late-breaking abstracts as they are presented at the meeting.
Scroll down to find videos on oncogene-addicted NSCLC, prostate cancer, gastric cancer, breast cancer and ovarian cancer
Elizabeth (Lizzy) Smyth is a consultant in gastrointestinal oncology. Dr Smyth commenced her oncology training in Dublin, Ireland. In 2009 she was awarded a fellowship from the Irish Society of Medical Oncology to train at Memorial Sloan-Kettering Centre, New York. Following this, she worked at the Royal Marsden Hospital in London from 2011-2018. Her research focus is on clinical trials and translational research in gastroesophageal cancer, and she has worked on trial design and management of national and international trials. She is a member of the European Society for Medical Oncology GI Faculty and leads the EORTC GI Trials Group Gastric Cancer Taskforce. Dr Smyth is committed to furthering national and international collaboration in GI trials research.
Amal Therapeutics, Aptitude Health, Amgen, Astellas, Astra Zeneca, Beigene, BMS, Celgene, Daiichi Sankyo, Elsevier, Everest Clinical Research, First Word Group, Five Prime Therapeutics, Gritstone Oncology, Imedex, Merck, My Personal Therapeutics, Novartis, Pfizer, Roche, Sai-Med, Servier, Viracta, Zymeworks
Duration
1 MIN
Language(s)
Prof. Mark Socinski will talk to us about his views on the latest data on oncogene-addicted non-small cell lung cancer (NSCLC) presented at ASCO 2025.
Prof. Socinski is likely to review data from the following key studies:
Check back soon to see Prof. Socinski's short video, key clinical takeaways, and downloadable slide set.
Prof. Mark Socinski is a Medical Oncologist and Executive Medical Director of the AdventHealth Cancer Institute, Orlando, Florida. Specialises in all thoracic malignancies, including small cell and non-small cell lung cancers and mesothelioma. An internationally recognised expert in the development of novel chemotherapy agents and treatment strategies for advanced non-small cell lung cancer and small cell lung cancer. Research has focused on incorporating personalised medicine and molecular biomarkers in the treatment of lung cancer. Formerly Co-Chair of the Thoracic Malignancies Steering Committee for the National Cancer Institute and served on the Respiratory Core Committee of the Cancer and Leukemia Group B (Alliance). Tenured Professor at the University of North Carolina and the University of Pittsburgh.
AstraZeneca, BMS, Eli Lilly, Genentech, GI Therapeutics, Guardant, Janssen, Jazz, Merck, Novartis.
Duration
MIN
Language(s)
LUNG CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Pierre Fabre Laboratories and Boehringer Ingelheim.
Meet the experts
Dr Lizzy Smyth will share her views on practice-changing gastric cancer data as they emerge from the ASCO 2025 congress.
She is anticipated to review new findings from the MATTERHORN and DESTINY-Gastric04 studies and pick out her key clinical takeaways from both.
Elizabeth (Lizzy) Smyth is a consultant in gastrointestinal oncology. Dr Smyth commenced her oncology training in Dublin, Ireland. In 2009 she was awarded a fellowship from the Irish Society of Medical Oncology to train at Memorial Sloan-Kettering Centre, New York. Following this, she worked at the Royal Marsden Hospital in London from 2011-2018. Her research focus is on clinical trials and translational research in gastroesophageal cancer, and she has worked on trial design and management of national and international trials. She is a member of the European Society for Medical Oncology GI Faculty and leads the EORTC GI Trials Group Gastric Cancer Taskforce. Dr Smyth is committed to furthering national and international collaboration in GI trials research.
Amal Therapeutics, Aptitude Health, Amgen, Astellas, Astra Zeneca, Beigene, BMS, Celgene, Daiichi Sankyo, Elsevier, Everest Clinical Research, First Word Group, Five Prime Therapeutics, Gritstone Oncology, Imedex, Merck, My Personal Therapeutics, Novartis, Pfizer, Roche, Sai-Med, Servier, Viracta, Zymeworks
Duration
MIN
Language(s)
GI CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Ipsen, BeiGene Europe and Pierre Fabre Laboratories.
Meet the experts
Dr Paolo Tarantino is joining us at ASCO to share expert insights on new breast cancer data from ASCO 2025.
Check back soon to see his video update and find out how he thinks these new data could impact clinical practice.
Dr Tarantino is expected to share his thoughts on the SERENA-6, DESTINY-Breast09 and VERITAC-2 studies:
Paolo Tarantino is a leading researcher in the field of breast cancer and drug development. He’s currently pursuing an advanced research fellowship at Dana Farber Cancer Institute and at Harvard Medical School (Boston, MA) and a PhD in clinical research at the University of Milan. His research focuses on the study of the HER2 oncoprotein, the biology of HER2-low breast tumors and the development of novel antibody-drug conjugates.
Dr. Tarantino decleares advisory role, speakers fees and/or research support from: AstraZeneca, Daiichi Sankyo, Lilly and Gilead.
Duration
MIN
Language(s)
BREAST CANCER CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Menarini Stemline Oncology, AstraZeneca and Thermo Fisher Scientific.
Meet the experts
Prof. Domenica Lorusso is joining us at ASCO 2025 to give her insights into how new data presented at the meeting might impact clinical practice.
Prof. Lorusso could report on ovarian cancer data from the Phase 3 FIRST/ENGOT-OV44, ROSELLA and TRUST studies:
Dr Domenica "Ketta" Lorusso obtained her degree in Medicine and Surgery in 1995, her residency in Obstetrics and Gynecology in 1999 and her PhD in Obstetrics and Gynecology in 2003. She is currently Associate Professor of Obstetrics and Gynecology at the Catholic University of Rome and responsible for clinical research at Fondazione Policlinico Gemelli IRCCS.
She is an active member of the European Network of Gynaecological Oncological Trial groups (ENGOT), where she leads the Gynecological Cancer Academy (since 2020). Dr Lorusso is a member of the Board of Directors of the Gynecologic Cancer InterGroup (GCIG), where she is the past chair of the Endometrial Cancer Committee and the Nomination and Meeting Committee. Currently, she is a member of the ESGO Council and scientific coordinator of the ESMO Gynaecological Cancers Congress. She is involved in preclinical and clinical research in gynaecological cancer, and she is the author of more than 250 papers on gynaecological cancers. Her work has hugely contributed to improving the quality of care and clinical outcome and to reducing the toxicity of treatments in women with advanced gynaecological malignancies.
MSD, GSK, Novartis, Clovis Oncology, AstraZeneca, Eisai, PharmaMar, ImmunoGen, Genmab
Duration
MIN
Language(s)
OBSTETRICS & GYNECOLOGY CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Eisai Europe Ltd, Aspivix and Novo Nordisk.
Meet the experts
Prof. Gerhardt Attard will join us at ASCO after he presents new data in metastatic castration-sensitive prostate cancer from the Phase 3 AMPLITUDE study.
Check back soon to get his expert insights into what these data mean for mCSPC management.
Prof. Attard is a Cancer Research UK Clinician Scientist and Team Leader at The Institute of Cancer Research and an Honorary Medical Oncology Consultant at the Royal Marsden NHS Foundation Trust, London, UK. He graduated with a degree in Medicine from the University of Malta in June 1999 and obtained a PhD in Medicine from the University of London (ICR) in 2010. His main research interest is dissecting treatment resistance, currently with a focus on plasma DNA analysis, in order to inform on the development of novel therapeutics and biomarkers for castration-resistant prostate cancer (CRPC). He is an experienced clinical trialist in CRPC and a co-author of more than 100 peer-reviewed manuscripts, including several important papers on advanced prostate cancer. Prof. Attard’s many awards over the years include the ASCO Foundation Annual Merit Award in 2007, Prostate Cancer Foundation Young Investor Award in 2008, the AACR-GlaxoSmithKline Outstanding Clinical Scholar Award in 2009, the Medical Research Society/Academy of Medical Sciences Sue McCarthy Prize in 2010 and the McElwain award in 2010. Prof. Attard sits on a number of advisory boards and the editorial board of Annals of Oncology.
Grants or contracts from Astellas Pharma, Blue Earth Therapeutics, Janssen, Veracye and Novartis
Consulting fees from Amgen, AstraZeneca, Astellas Pharma, Bayer, Blue Earth Therapeutics, Janssen-Cilag, Merck & Co, Merck Sorono Ltd, Novartis, Pfizer, Veracyte.
Payment or honoraria from Astellas Pharma, Janssen, Astrazeneca, Sanofi, Sandoz.
Support for attending meetings/travel from Amgen, Astellas Pharma, Bayer, Janssen, Merck Sorono Ltd, Pfizer
On the Institute of Cancer Research Discoveries list of abiraterone acetate. Listed as inventor on docetaxel predictive, biomarker (Veracyte).
Listed as inventor on patent related to blood biomarkers (UCL, Cancer Research Horizons)
Commercial agreements with employer, UCL with Artera and Veracyte
Duration
MIN
Language(s)
GU CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.
Meet the experts
Symposium
Medical experts discuss treatment strategies and sequencing after ET + CDK4/6i for ER+/HER2- metastatic breast cancer
Downloadable 
5 MIN
May 2025 
Podcast
Experți de renume din domeniul medical își împărtășesc perspectivele. Navigați în secțiuni pentru a selecta un episod al podcastului
Downloadable
21 MIN
May 2025 
Video
Improving the survival of patients with relapsed/refractory multiple myeloma
Downloadable
2 MIN
May 2025
Animated Video
Expert insights into personalised treatment strategies in BRAF-mutated NSCLC
Downloadable
6 MIN
May 2025
Podcast
Chemotherapy strategies that matter
Downloadable
4 MIN
May 2025
Podcast
Insights and support for patients
Downloadable
4 MIN
May 2025
